US FDA orphan designation received for cutaneous porphyrias
Filed with ASX · · 2 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Update on North American vitiligo program for SCENESSE
- TGA grants Orphan Drug Designation for SCENESSE
- Swiss insurers agree to reimburse Clinuvel`s SCENESSE
- SCENESSE released for European Distribution
- SCENESSE Commercialisation Update
Later from Clinuvel Pharmaceuticals
- Clinuvel brief on European commercialisation
- Clinuvel Placement
- Clinuvel accredits first European EPP expert centres
- Clinuvel enters a joint venture with Biotech Lab Singapore
- EMA Oral Explanation Update
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals